Adjuvant radiotherapy after brain metastasectomy: analysis of consecutive cohort of 118 patients from real world practice

. 2024 ; 29 (1) : 30-41. [epub] 20240318

Status PubMed-not-MEDLINE Jazyk angličtina Země Polsko Médium electronic-ecollection

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/pmid39165600

BACKGROUND: The aim of this retrospective study is to analyze a consecutive cohort of brain metastasis (BM) patients treated off clinical trials through combination of surgery and radiotherapy over the last 15 years in a tertiary neurooncology center. MATERIALS AND METHODS: All BM patients operated between 2007-2019 received adjuvant linac-based radiotherapy categorized to whole brain radiotherapy (WBRT) and tumor bed stereotactic radiotherapy. Survival outcomes and local control was analyzed. RESULTS: In total, 118 patients were enrolled, those with stereotactic radiotherapy (41%) had better baseline characteristics mirrored in longer overall survival (OS) [18 vs. 7.1 months, p < 0.001; hazard ratio (HR) 0.47, p = 0.004] with median follow-up of 58 months. Cumulative incidence for local, distant, and extracranial control was not significantly different between groups, with 12-month cumulative control of 22% vs. 18%, 44% vs. 29%, and 35% vs. 32% for stereotactic and WBRT group, respectively. WBRT was an independent factor for better distal brain control. CONCLUSIONS: Real world data demonstrating significantly better overall survival in patients treated with postoperative targeted radiotherapy compared with postoperative WBRT is presented, with no significant difference in cumulative incidence for local or distant brain control. The majority of patients with targeted radiotherapy had a fractionated dose schedule with outcomes comparable to single-dose radiation trials of postoperative targeted radiotherapy.

Zobrazit více v PubMed

Lamba N, Wen PY, Aizer AA. Epidemiology of brain metastases and leptomeningeal disease. Neuro Oncol. 2021;23(9):1447–1456. doi: 10.1093/neuonc/noab101. PubMed DOI PMC

Erickson AW, Brastianos PK, Das S. Assessment of Effectiveness and Safety of Osimertinib for Patients With Intracranial Metastatic Disease: A Systematic Review and Meta-analysis. JAMA Netw Open. 2020;3(3):e201617. doi: 10.1001/jamanetworkopen.2020.1617. PubMed DOI PMC

Ramalingam SS, Vansteenkiste J, Planchard D, et al. FLAURA Investigators. Programmed Cell Death Ligand 1 Expression in Untreated EGFR Mutated Advanced NSCLC and Response to Osimertinib Versus Comparator in FLAURA. J Thorac Oncol. 2020;15(1):138–143. doi: 10.1016/j.jtho.2019.09.009. PubMed DOI

Davies MA, Saiag P, Robert C, et al. Dabrafenib plus trametinib in patients with BRAF-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. Lancet Oncol. 2017;18(7):863–873. doi: 10.1016/S1470-2045(17)30429-1. PubMed DOI PMC

Long GV, Atkinson V, Lo S, et al. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. Lancet Oncol. 2018;19(5):672–681. doi: 10.1016/S1470-2045(18)30139-6. PubMed DOI

Murthy RK, Loi S, Okines A, et al. Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. N Engl J Med. 2020;382(7):597–609. doi: 10.1056/NEJMoa1914609. PubMed DOI

Aizer AA, Lamba N, Ahluwalia MS, et al. Brain metastases: A Society for Neuro-Oncology (SNO) consensus review on current management and future directions. Neuro Oncol. 2022;24(10):1613–1646. doi: 10.1093/neuonc/noac118. PubMed DOI PMC

Vogelbaum MA, Brown PD, Messersmith H, et al. Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline. J Clin Oncol. 2022;40(5):492–516. doi: 10.1200/JCO.21.02314. PubMed DOI

Le Rhun E, Guckenberger M, Smits M, et al. EANO Executive Board and ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours. Ann Oncol. 2021;32(11):1332–1347. doi: 10.1016/j.annonc.2021.07.016. PubMed DOI

R: The R Project for Statistical Computing. [15 February 2023]. https://www.r-project.org/

Kazda T, Jancalek R, Pospisil P, et al. Why and how to spare the hippocampus during brain radiotherapy: the developing role of hippocampal avoidance in cranial radiotherapy. Radiat Oncol. 2014;9:139. doi: 10.1186/1748-717X-9-139. PubMed DOI PMC

Lakomy R, Hynkova L, Pospisil P, et al. Patterns of failure after brain metastases radiotherapy: reflections on the importance for treatment and clinical trials reporting. Neoplasma. 2017;64(3):329–337. doi: 10.4149/neo_2017_302. PubMed DOI

Brown PD, Ballman KV, Cerhan JH, et al. Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC·3): a multicentre, randomised, controlled, phase 3 trial. Lancet Oncol. 2017;18(8):1049–1060. doi: 10.1016/S1470-2045(17)30441-2. PubMed DOI PMC

Mahajan A, Ahmed S, McAleer MF, et al. Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases: a single-centre, randomised, controlled, phase 3 trial. Lancet Oncol. 2017;18(8):1040–1048. doi: 10.1016/S1470-2045(17)30414-X. PubMed DOI PMC

Traylor JI, Habib A, Patel R, et al. Fractionated stereotactic radiotherapy for local control of resected brain metastases. J Neurooncol. 2019;144(2):343–350. doi: 10.1007/s11060-019-03233-9. PubMed DOI

Minniti G, Niyazi M, Andratschke N, et al. Current status and recent advances in resection cavity irradiation of brain metastases. Radiat Oncol. 2021;16(1):73. doi: 10.1186/s13014-021-01802-9. PubMed DOI PMC

Patchell RA, Tibbs PA, Regine WF, et al. Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA. 1998;280(17):1485–1489. doi: 10.1001/jama.280.17.1485. PubMed DOI

Mahajan A, Ahmed S, McAleer MF, et al. Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases: a single-centre, randomised, controlled, phase 3 trial. Lancet Oncol. 2017;18(8):1040–1048. doi: 10.1016/S1470-2045(17)30414-X. PubMed DOI PMC

Kayama T, Sato S, Sakurada K, et al. Japan Clinical Oncology Group. Effects of Surgery With Salvage Stereotactic Radiosurgery Versus Surgery With Whole-Brain Radiation Therapy in Patients With One to Four Brain Metastases (JCOG0504): A Phase III, Noninferiority, Randomized Controlled Trial. J Clin Oncol. 2018:JCO2018786186. doi: 10.1200/JCO.2018.78.6186. [Epub ahead of print] PubMed DOI

Kepka L, Tyc-Szczepaniak D, Osowiecka K, et al. Stereotactic radiotherapy of the tumor bed compared to whole brain radiotherapy after surgery of single brain metastasis: Results from a randomized trial. Radiother Oncol. 2016;121(2):217–224. doi: 10.1016/j.radonc.2016.10.005. PubMed DOI

Palmer JD, Klamer BG, Ballman KV, et al. Association of Long-term Outcomes With Stereotactic Radiosurgery vs Whole-Brain Radiotherapy for Resected Brain Metastasis: A Secondary Analysis of The N107C/CEC.3 (Alliance for Clinical Trials in Oncology/Canadian Cancer Trials Group) Randomized Clinical Trial. JAMA Oncol. 2022;8(12):1809–1815. doi: 10.1001/jamaoncol.2022.5049. PubMed DOI PMC

Prabhu R, Shu HK, Hadjipanayis C, et al. Current dosing paradigm for stereotactic radiosurgery alone after surgical resection of brain metastases needs to be optimized for improved local control. Int J Radiat Oncol Biol Phys. 2012;83(1):e61–e66. doi: 10.1016/j.ijrobp.2011.12.017. PubMed DOI

Bachmann N, Leiser D, Ermis E, et al. Impact of regular magnetic resonance imaging follow-up after stereotactic radiotherapy to the surgical cavity in patients with one to three brain metastases. Radiat Oncol. 2019;14(1):45. doi: 10.1186/s13014-019-1252-x. PubMed DOI PMC

Robbins JR, Ryu S, Kalkanis S, et al. Radiosurgery to the surgical cavity as adjuvant therapy for resected brain metastasis. Neurosurgery. 2012;71(5):937–943. doi: 10.1227/NEU.0b013e31826909f2. PubMed DOI

Brennan C, Yang TJ, Hilden P, et al. A phase 2 trial of stereotactic radiosurgery boost after surgical resection for brain metastases. Int J Radiat Oncol Biol Phys. 2014;88(1):130–136. doi: 10.1016/j.ijrobp.2013.09.051. PubMed DOI PMC

Strauss I, Corn BW, Krishna V, et al. Patterns of Failure after Stereotactic Radiosurgery of the Resection Cavity Following Surgical Removal of Brain Metastases. World Neurosurg. 2015;84(6):1825–1831. doi: 10.1016/j.wneu.2015.07.073. PubMed DOI

Eaton BR, LaRiviere MJ, Kim S, et al. Hypofractionated radiosurgery has a better safety profile than single fraction radiosurgery for large resected brain metastases. J Neurooncol. 2015;123(1):103–111. doi: 10.1007/s11060-015-1767-4. PubMed DOI

Brown PD, Gondi V, Pugh S, et al. for NRG Oncology. Hippocampal Avoidance During Whole-Brain Radiotherapy Plus Memantine for Patients With Brain Metastases: Phase III Trial NRG Oncology CC001. J Clin Oncol. 2020;38(10):1019–1029. doi: 10.1200/JCO.19.02767. PubMed DOI PMC

El Shafie RA, Celik A, Weber D, et al. A matched-pair analysis comparing stereotactic radiosurgery with whole-brain radiotherapy for patients with multiple brain metastases. J Neurooncol. 2020;147(3):607–618. doi: 10.1007/s11060-020-03447-2. PubMed DOI

Fogarty GB, Hong A, Gondi V, et al. Debate: adjuvant whole brain radiotherapy or not? More data is the wiser choice. BMC Cancer. 2016;16:372. doi: 10.1186/s12885-016-2433-8. PubMed DOI PMC

Najít záznam

Citační ukazatele

Možnosti archivace